News About: Pharm. Industry
The number of Korean pharmaceutical companies’ patent applications reaches only up to 18%of what multinational companies have
It was shown that the ratio of Korean pharmaceutical companies’ patent applications against multinational pharm companies is less than 20%.
According to the ‘patent application survey of domestic pharmaceutical compa...
LG Life Science’s partnership for the ‘Humira biosimilar’ with Mochida in Japan
On the 15th, LG Life Science Ltd. (CEO: Il-jae Jung) announced that it made a partnership with a Japanese company, Mochida, to develop and sell the Humira biosimilar, a global drug for autoimmune disease.
Through the...
A strategy to own twin drugs through Korean domestic branches spreads in the pharmaceutical industry
Korean pharmaceutical companies owning original medicines are getting ready for the patent expirations in various ways, too.
Several companies are implementing a strategy to commercialize twin medicines with the same...
The ‘Usage-Medicine Price Linkage system’, interrupting overseas expansion of new medicines, such as Kanarb and Noltec
Since the Usage-Medicine Price Linkage system gets in the way of overseas expansion of new medicines, comments about preparing countermeasures for the issue brought up at the national inspection.
The Usage-Medicine P...
Will blockbusters of the pharmaceutical industry breathe life into the generic market?
The new generic market estimated at KRW 350 billion will be opened next year.
According to the 2015 Pharmaceutical Bio Industry Prospect Report, published by Shinhan Investment Corporation on the 13th, it was anticip...
Entering to the U.S. market will be visualize as 10 companies are undergoing challenges to get FDA’s approvals
Korean pharmaceutical companies will hit stride in their global challenges targeting the U.S. market.
As the impotency drug that Mezzion, a new drug development company, made partnership with Actavis is expected to b...
Seriousness of a new type of illegal rebates provided by CSO
Although the government has enforced various regulations to eradicate illegal rebates for medicines, it was indicated that the third illegal rebate, called Contract Sales Organization (hereinafter referring to CSO), i...
The flu vaccine of Green Cross will exceed yearly sales in excess of KRW 100 billion
Since Green Cross produced the first influenza vaccine five years ago at the Hwasoon factory in Jeollanam-do in 2009 as the very first domestic pharmaceutical company, it has passed producing 100 million doses of infl...
The pharmaceutical industry is no longer available to operate rebate businesses
“Rebate sales marketing is no longer available in the pharmaceutical industry. This is because making funds for rebates is not an option anymore.” The statement was quoted by a CEO of a medium-sized pharmaceutical com...
‘Attention’ on IPOs of pharmaceutical companies’ branches in succession
Branches of pharmaceutical companies have drawn people’s attention with filing initial public offerings (IPO).
According to the industry concerned on the 13th, Green Cross MS, a branch of Green Cross, Humedix, a bran...
